Jane Q. Yap

Jane Q. Yap

Auto-generated profile, based on publicly available information

Jane Q. Yap

Department of Quantitative Health Sciences Mayo Clinic Jacksonville Florida USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2025 in The American Journal of Bioethics
Verified
Journal Article
Open access
MAMegan A. Allyse
Megan A. Allyse
PAPreya Agam
Preya Agam
YBYvonne Bombard
Yvonne Bombard
RFRoel Feys
Roel Feys
MHMcKenna Horstmann
McKenna Horstmann
JYJane Q. Yap
Jane Q. Yap
Despite considerable scientific progress and the evolution of regulatory pathways to ensure safety and efficacy, US healthcare continues to see increasing health disparities. This suggests that clinical translation in of itself cannot be the only measure of its own success, especially when the most marginalized patients, are neglected in the development and implementation of medical innovations. This raises the question of whether a system that is narrowly focused on technical achievement can meet the moral obligations of medicine and public health. We argue that traditional technocratic standards are failing to integrate normative considerations into biomedical translation. What is needed is a translational domain that moves beyond safety and efficacy toward anticipating how proposed technologies will be effective in society as it exists. We propose an additional metric of success: translational justice.

Verified
Journal Article
Open access
PDF file
PDPhilippe F. Delmotte
Philippe F. Delmotte
JYJane Q. Yap
Jane Q. Yap
DDDebanjali Dasgupta
Debanjali Dasgupta
GSGary Sieck
Gary Sieck
Airway inflammation and pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFα) underlie the pathophysiology of respiratory diseases, including asthma. Previously, we showed that TNFα activates the inositol-requiring enzyme 1α (IRE1α)/X-box binding protein 1 spliced (XBP1s) endoplasmic reticulum (ER) stress pathway in human airway smooth muscle (hASM) cells. The ER stress pathway is activated by the accumulation of unfolded proteins in the ER. Accordingly, chemical chaperones such as 4-phenylbutyric acid (4-PBA) may reduce ER stress activation. In the present study, we hypothesized that chemical chaperone 4-PBA mitigates TNFα-induced ER stress in hASM cells. hASM cells were isolated from bronchiolar tissue obtained from five patients with no history of smoking or respiratory diseases. The hASM cells’ phenotype was confirmed via the expression of alpha-smooth muscle actin and elongated morphology. hASM cells from the same patient sample were then separated into three 12 h treatment groups: (1) TNFα (20 ng/mL), (2) TNFα + 4-PBA (1 μM, 30 min pretreatment), and (3) untreated control. The expressions of total IRE1α and phosphorylated IRE1α (pIRE1αS724) were determined through Western blotting. The splicing of XBP1 mRNA was analyzed using RT-PCR. We found that TNFα induced an increase in pIRE1αS724 phosphorylation, which was mitigated by treatment with chemical chaperone 4-PBA. We also found that TNFα induced an increase in XBP1s mRNA, which was also mitigated by treatment with chemical chaperone 4-PBA. These results support our hypothesis and indicate that chemical chaperone 4-PBA treatment mitigates TNFα-induced ER stress in hASM cells.

Verified
Journal Article
Open access
PDF file
SBSanjana Mahadev Bhat
Sanjana Mahadev Bhat
JYJane Q. Yap
Jane Q. Yap
OROscar A. Ramirez-Ramirez
Oscar A. Ramirez-Ramirez
PDPhilippe F. Delmotte
Philippe F. Delmotte
GSGary Sieck
Gary Sieck
Cellular mitochondrial function can be assessed using high-resolution respirometry that measures the O2 consumption rate (OCR) across a number of cells. However, a direct measurement of cellular mitochondrial function provides valuable information and physiological insight. In the present study, we used a quantitative histochemical technique to measure the activity of succinate dehydrogenase (SDH), a key enzyme located in the inner mitochondrial membrane, which participates in both the tricarboxylic acid (TCA) cycle and electron transport chain (ETC) as Complex II. In this study, we determine the maximum velocity of the SDH reaction (SDHmax) in individual human airway smooth muscle (hASM) cells. To measure SDHmax, hASM cells were exposed to a solution containing 80 mM succinate and 1.5 mM nitroblue tetrazolium (NBT, reaction indicator). As the reaction proceeded, the change in optical density (OD) due to the reduction of NBT to its diformazan (peak absorbance wavelength of 570 nm) was measured using a confocal microscope with the pathlength for light absorbance tightly controlled. SDHmax was determined during the linear period of the SDH reaction and expressed as mmol fumarate/liter of cell/min. We determine that this technique is rigorous and reproducible, and reliable for the measurement of mitochondrial function in individual cells.

20 March 2025 in Psycho-Oncology
Verified
Journal Article
Closed access
JYJane Q. Yap
Jane Q. Yap
KRKirsten A. Riggan
Kirsten A. Riggan
ECEwan K. Cobran
Ewan K. Cobran
MHMichele Y. Halyard
Michele Y. Halyard
SJSarah E. James
Sarah E. James
MAMegan A. Allyse
Megan A. Allyse

13 August 2026 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
JYJane Q. Yap
Jane Q. Yap
SLShannon K. Laughlin-Tommaso
Shannon K. Laughlin-Tommaso
In this clinical perspective, we examine the role of gonadotropin-releasing hormone (GnRH) antagonist combination therapies in the management of uterine leiomyomas during perimenopause, a period marked by hormonal variability and heightened symptom burden. Drawing on mechanistic comparisons, randomized trial data, and long-term safety findings, we review evidence demonstrating that GnRH antagonist combination therapies provide rapid, reversible suppression of gonadotropin secretion without an estrogen flare. This, in turn, results in consistent reductions in heavy menstrual bleeding associated with leiomyomas, management of bulk-related symptoms, and improvement with anemia. We further highlight limitations of conventional hormonal and expectant management strategies during perimenopause and discuss practical considerations for patient selection and monitoring. Collectively, these findings support GnRH antagonist combination therapy as a targeted, time-limited, and well-tolerated treatment option that addresses a critical therapeutic gap for perimenopausal patients with symptomatic uterine leiomyomas.

5 March 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JYJane Q. Yap
Jane Q. Yap
JRJhenitza P. Raygoza
Jhenitza P. Raygoza
VHValentina Hernandez
Valentina Hernandez
CGCrystal Gonzalez
Crystal Gonzalez
CVCeline Vachon
Celine Vachon
JAJessica Danielle Austin
Jessica Danielle Austin
Introduction: Breast cancer remains a leading cause of death among Latinas. Although breast cancer risk assessment models exist and show promise in reducing mortality, few studies have elicited women's interest in and perceptions around breast cancer risk assessment, particularly among underserved populations, like Latinas, who are susceptible to disparities in breast cancer outcomes. These disparities stem from factors such as limited access to healthcare services, lower rates of screening utilization, language barriers, and socioeconomic challenges, all of which compound their risk and hinder effective engagement with risk assessment tools. This qualitative study aims to explore Latinas' perspectives regarding breast cancer risk assessment and implications on future behaviors. Methods: Twenty‐three under‐ or uninsured Latinas aged 45–65 with no personal history of breast cancer took part in either a focus group ( n = 3, 15 participants) or individual interviews (8 participants). Guided by health behavior theories (Theory of Planned Behavior and Health Belief Model), data were transcribed, translated, and analyzed using a deductive‐inductive approach to thematic content analysis, resulting in four themes. Results: Latinas expressed high interest in knowing their breast cancer risk and reported that the benefits of knowing one's risk outweighed the harms. Latinas also stated that they would continue screening as recommended if found to be at low risk, but that they would speak with their provider or increase screening frequency if found to be at increased risk. Moreover, Latinas described the pivotal role of providers and social networks in influencing interest and perceptions around breast cancer risk assessment and preventive behaviors. Conclusion: Underserved Latinas viewed breast cancer risk assessment positively and underscored the need for multilevel, culturally tailored strategies to improve breast cancer risk assessment. This study yielded four distinct themes: (1) Interest and Awareness of Personal Breast Cancer Risk, (2) Benefits and Barriers of Knowing Personal Breast Cancer Risk, (3) Screening Implications of Knowing Personal Breast Cancer Risk, and (4) Provider Influence on Breast Cancer Risk Assessment and Behaviors. Potential strategies include efforts to improve provider engagement and communication and leveraging social networks to increase awareness and encourage preventive behaviors. Trial Registration: NCI‐2023‐00465